2. Academic Validation
  3. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

  • Br J Cancer. 2024 Jan 26. doi: 10.1038/s41416-024-02586-x.
Marcell Baranyi 1 2,  Eszter Molnár 1,  Luca Hegedűs 3,  Zsófia Gábriel 1 4,  Flóra Gréta Petényi 1 4,  Fanni Bordás 1 5,  Violetta Léner 2,  Ivan Ranđelović 2 6,  Mihály Cserepes 2 6,  József Tóvári 6,  Balázs Hegedűs # 7 8,  József Tímár # 1
Affiliations

Affiliations

  • 1 Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091, Budapest, Hungary.
  • 2 KINETO Lab Ltd, H-1037, Budapest, Hungary.
  • 3 Department of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, D-45239, Essen, Germany.
  • 4 Pázmány Péter Catholic University Faculty of Information Technology and Bionics, H-1083, Budapest, Hungary.
  • 5 Department of Anatomy, Cell and Developmental Biology, Eötvös Loránd University, H-1117, Budapest, Hungary.
  • 6 Department of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, H-1122, Budapest, Hungary.
  • 7 Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091, Budapest, Hungary. Balazs.Hegedues@rlk.uk-essen.de.
  • 8 Department of Thoracic Surgery, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, D-45239, Essen, Germany. Balazs.Hegedues@rlk.uk-essen.de.
  • # Contributed equally.
PMID: 38278976 DOI: 10.1038/s41416-024-02586-x
Abstract

Background: Inhibition of mutant KRAS challenged Cancer research for decades. Recently, allele-specific inhibitors were approved for the treatment of KRAS-G12C mutant lung Cancer. However, de novo and acquired resistance limit their efficacy and several combinations are in clinical development. Our study shows the potential of combining G12C inhibitors with farnesyl-transferase inhibitors.

Methods: Combinations of clinically approved farnesyl-transferase inhibitors and KRAS G12C inhibitors are tested on human lung, colorectal and pancreatic adenocarcinoma cells in vitro in 2D, 3D and subcutaneous xenograft models of lung adenocarcinoma. Treatment effects on migration, proliferation, Apoptosis, farnesylation and Ras signaling were measured by histopathological analyses, videomicroscopy, cell cycle analyses, immunoblot, immunofluorescence and Ras pulldown.

Results: Combination of tipifarnib with sotorasib shows synergistic inhibitory effects on lung adenocarcinoma cells in vitro in 2D and 3D. Mechanistically, we present antiproliferative effect of the combination and interference with compensatory HRAS activation and RHEB and lamin farnesylation. Enhanced efficacy of sotorasib in combination with tipifarnib is recapitulated in the subcutaneous xenograft model of lung adenocarcinoma. Finally, combination of additional KRAS G1C and farnesyl-transferase inhibitors also shows synergism in lung, colorectal and pancreatic adenocarcinoma cellular models.

Discussion: Our findings warrant the clinical exploration of KRAS-G12C inhibitors in combination with farnesyl-transferase inhibitors.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z